Beta-2 Microglobulin in ESRD: An In-Depth Review

Advances in Renal Replacement Therapy

Volumn 10, Issue 4, 2003, Pages 279-309

  Winchester, James F ^a   Salsberg, Jamie A ^b   Levin, Nathan W ^b  

^a RenalTech International   (United States)

^b NONE

Author keywords

Amyloidosis; Beta 2 microglobulin; DRA; High flux dialysis; Inflammation; Sorbents

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CORTICOSTEROID; CYTOKINE; HEMODIALYSIS FLUID; HLA ANTIGEN CLASS 1; INTERLEUKIN 1; INTERLEUKIN 6; IRON; POLY(METHYL METHACRYLATE); POLYSULFONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UREMIC TOXIN;

ADSORPTION; AMYLOIDOSIS; ARTIFICIAL KIDNEY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARPAL TUNNEL SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DIALYSIS; DIALYSIS MEMBRANE; FIBER; GLYCOSYLATION; HEART VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; INFLAMMATION; IRON THERAPY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; KINETICS; META ANALYSIS; MORBIDITY; MORTALITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN AGGREGATION; PROTEIN METABOLISM; REVIEW; RISK REDUCTION; ULTRAFILTRATION;

EID: 0346157033     PISSN: 10734449     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.arrt.2003.11.003     Document Type: Article

References (173)

1. Vanholder RC, Ringoir SM: Adequacy of dialysis: a critical analysis. Kidney Int 42:540-558, 1992
2. Eknoyan G, Beck GJ, Cheung AK, et al: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347:2010-2019, 2002
3. Berman HM, Westbrook J, Feng Z, et al: The Protein Data Bank. Nucl Acids Res 28:235-242, 2002
4. Haufe CC, Eismann U, Deppisch RM, et al: Expression of beta2-microglobulin and c-fos mRNA: Is there an influence of high- or low-flux dialyzer membranes? Kidney Int Suppl 78:S177-181, 2001
5. Karlsson FA, Wibell L, Evrin PE: Beta 2-microglobulin in clinical medicine. Scand J Clin Lab Invest Suppl 154:27-37, 1980
6. Kanamori T, Sakai K: An estimate of beta 2-microglobulin deposition rate in uremic patients on hemodialysis using a mathematical kinetic model. Kidney Int 47:1453-1457, 1995
7. Gotch FA: Kinetics of solute removal in hemodialysis, in Ringoir S, Vanholder R, Massry SG (eds): Uremic Toxins. New York, NY, Plenum Press, 1987, pp 227-237
8. Floege J, Bartsch A, Schulze M, et al: Clearance and synthesis rates of beta 2-microglobulin in patients undergoing hemodialysis and in normal subjects. J Lab Clin Med 118:153-165, 1991
9. Kabanda A, Jadoul M, Pochet JM, et al: Determinants of the serum concentration of low molecular weight proteins in patients on maintenance hemodialysis. Kidney Int 45:1689-1696, 1994
10. Chanard J, Vincent C, Caudwell V, et al: Beta 2-microglobulin metabolism in uremic patients who are undergoing dialysis. Kidney Int Suppl 41:S83-87, 1993
11. Vincent C, Chanard J, Caudwell V, et al: Kinetics of 125I-beta 2-microglobulin turnover in dialyzed patients. Kidney Int 42:1434-1443, 1992
12. Odell RA, Slowiaczek P, Moran JE, et al: Beta 2-microglobulin kinetics in end-stage renal failure. Kidney Int 39:909-919, 1991
13. Raj DS, Ouwendyk M, Francoeur R, et al: Beta(2)-microglobulin kinetics in nocturnal haemodialysis. Nephrol Dial Transplant 15:58-64, 2000
14. Vanholder R, Argiles A, Baurmeister U, et al: Uremic toxicity: Present state of the art. Int J Artif Organs 24:695-725, 2001
15. Jadoul M, Garbar C, Vanholder R, et al: Prevalence of histological beta2-microglobulin amyloidosis in CAPD patients compared with hemodialysis patients. Kidney Int 54:956-959, 1998
16. Smith DP, Radford SE: Role of the single disulphide bond of beta(2)-microglobulin in amyloidosis in vitro. Protein Sci 10:1775-1784, 2001
17. Trinh CH, Smith DP, Kalverda AP, et al: Crystal structure of monomeric human beta-2-microglobulin reveals clues to its amyloidogenic properties. Proc Natl Acad Sci U S A 99:9771-9776, 2002
18. Chiti F, De Lorenzi E, Grossi S, et al: A partially structured species of beta 2-microglobulin is significantly populated under physiological conditions and involved in fibrillogenesis. J Biol Chem 276: 46714-46721, 2001
19. Brancaccio D, Gallieni M, Niwa T, et al: Ultrastructural localization of advanced glycation end products and beta2-microglobulin in dialysis amyloidosis. J Nephrol 13:129-136, 2000
20. Miyata T, Jadoul M, Kurokawa K, et al: Beta-2 microglobulin in renal disease. J Am Soc Nephrol 9:1723-1735, 1998
21. Kazama JJ, Arakawa M, Gejyo F: Synovial inflammatory cells captured 131I-beta 2-microglobulin in patients with dialysis related amyloidosis. Amyloid 5:24-29, 1998
22. Takahashi T, Kato A, Ikegaya N, et al: Ultrasound changes of the carpal tunnel in patients receiving long-term hemodialysis: A cross-sectional and longitudinal study. Clin Nephrol 57:230-236, 2002
23. Chertow GM, Trimbur T, Karlson EW, et al: Performance characteristics of a dialysis-related amyloidosis questionnaire. J Am Soc Nephrol 7:1235-1240, 1996
24. Miyata T, Hori O, Zhang J, et al: The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 98:1088-1094, 1996
25. Chen NX, O'Neill KD, Niwa T, et al: Signal transduction of beta2m-induced expression of VCAM-1 and COX-2 in synovial fibroblasts. Kidney Int 61: 414-424, 2002
26. Niwa T: Dialysis-related amyloidosis: Pathogenesis focusing on AGE modification. Semin Dial 14:123-126, 2001
27. Gerdemann A, Lemke HD, Nothdurft A, et al: Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis. Clin Nephrol 54:276-283, 2000
28. Homma N, Gejyo F, Isemura M, et al: Collagen-binding affinity of beta-2-microglobulin, a pre-protein of hemodialysis-associated amyloidosis. Nephron 53:37-40, 1989
29. Ohashi K, Kisilevsky R, Yanagishita M: Affinity binding of glycosaminoglycans with beta(2)-microglobulin. Nephron 90:158-168, 2002
30. Moe SM, Singh GK, Bailey AM: Beta2-microglobulin induces MMP-1 but not TIMP-1 expression in human synovial fibroblasts. Kidney Int 57:2023-2034, 2000
31. Gejyo F, Yamada T, Odani S, et al: A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. Biochem Biophys Res Commun 129:701-706, 1985
32. Gejyo F, Homma N, Suzuki Y, et al: Serum levels of beta 2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. N Engl J Med 314:585-586, 1986
33. Gorevic PD, Munoz PC, Casey TT, et al: Polymerization of intact beta 2-microglobulin in tissue causes amyloidosis in patients on chronic hemodialysis. Proc Natl Acad Sci U S A 83:7908-7912, 1986
34. Miyata T, Inagi R, Wada Y, et al: Glycation of human beta 2-microglobulin in patients with hemodialysis-associated amyloidosis: identification of the glycated sites. Biochemistry 33:12215-12221, 1984
35. Jadoul M: Dialysis-related amyloidosis: Importance of biocompatibility and age. Nephrol Dial Transplant 13:61-64, 1998 (suppl)
36. Descamps-Latscha B, Jungers P, Witko-Sarsat V: Immune system dysregulation in uremia: Role of oxidative stress. Blood Purif 20:481-484, 2002
37. Himmelfarb J, Stenvinkel P, Ikizler TA, et al: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62:1524-1538, 2002
38. Pecoits-Filho R, Lindholm B, Stenvinkel P: The malnutrition, inflammation, and atherosclerosis (MIA) syndromeThe heart of the matter. Nephrol Dial Transplant 17(suppl):28-31, 2002
39. Fung F, Sherrard DJ, Gillen DL, et al: Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. Am J Kidney Dis 40:307-314, 2002
40. Memoli B, Minutolo R, Bisesti V, et al, for Collaborative Study Group on SMC Membrane. Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. Am J Kidney Dis 39:266-273, 2002
41. Tovbin D, Mazor D, Vorobiov M, et al: Induction of protein oxidation by intravenous iron in hemodialysis patients: Role of inflammation. Am J Kidney Dis 40:1005-1012, 2002
42. Matsuo K, Ikizler TA, Hoover RL, et al: Transforming growth factor-beta is involved in the pathogenesis of dialysis-related amyloidosis. Kidney Int 57: 697-708, 2000
43. Sepittle MA, Hoenich NA, Handelman GJ, et al: Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 38:1408-1413, 2000
44. Yeun JY, Levine RA, Mantadilok V, et al: C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35: 469-476, 2000
45. Park CW, Shin YS, Kim CM, et al: Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. Am J Kidney Dis 40:1230-1239, 2002
46. Wanner C: C-reactive protein risk prediction: Adding cardiac hypertrophy to the list. Am J Kidney Dis 40:1340-1341, 2002
47. Bologa RM, Levine DM, Parker TS, et al: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32:107-114, 1998
48. Pecoits-Filho R, Barany P, Lindholm B, et al: Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 17:1684-1688, 2002
49. Stenvinkel P, Heimburger O, Jogestrand T: Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: Association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis 39:274-282, 2002
50. Kato A, Odamaki M, Takita T, et al: Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. Kidney Int 61:1143-1152, 2002
51. Kaysen G: Role of inflammation and its treatment in ESRD patients. Blood Purif 20:70-80, 2002
52. Aygunduz M, Bavbek N, Ozturk M, et al: Serum beta 2-microglobulin reflects disease activity in Behcet's disease. Rheumatol Int 22:5-8, 2002
53. Hou FF, Owen WF Jr: Beta 2-microglobulin amyloidosis: Role of monocytes/macrophages. Curr Opin Nephrol Hypertens 11:417-421, 2002
54. Chiou YY, Chiu NT, Chen MJ, et al: Role of beta 2-microglobulinuria and microalbuminuria in pediatric febrile urinary tract infection. Acta Paediatr Taiwan 42:84-89, 2001
55. Kobayashi S, Yoshida K, Ward JM, et al: Beta 2-microglobulin-deficient background ameliorates lethal phenotype of the TGF-beta 1 null mouse. J Immunol 163:4013-4019, 1999
56. Vraetz T, Ittel TH, van Mackelenbergh MG, et al: Regulation of beta2-microglobulin expression in different human cell lines by proinflammatory cytokines. Nephrol Dial Transplant 14:2137-2143, 1999
57. Mogi M, Otogoto J, Ota N, et al: Interleukin 1 beta, interleukin 6, beta 2-microglobulin, and transforming growth factor-alpha in gingival crevicular fluid from human periodontal disease. Arch Oral Biol 44:535-539, 1999
58. Lavi E, Das Sarma J, Weiss SR: Cellular reservoirs for coronavirus infection of the brain in beta2-microglobulin knockout mice. Pathobiology 67:75-83, 1999
59. Taylor SF, Cottey RJ, Zander DS, et al: Influenza infection of beta 2-microglobulin-deficient (beta 2m-/-) mice reveals a loss of CD4+ T cell functions with aging. J Immunol 159:3453-3459, 1997
60. Ladel CH, Flesch IE, Arnoldi J, et al: Studies with MHC-deficient knock-out mice reveal impact of both MHC I- and MHC II-dependent T cell responses on Listeria monocytogenes infection. J Immunol 153: 3116-3122, 1994
61. Moos T, Trinder D, Morgan EH: Cellular distribution of ferric iron, ferritin, transferrin and divalent metal transporter 1 (DMT1) in substantia nigra and basal ganglia of normal and beta2-microglobulin deficient mouse brain. Cell Mol Biol (Noisy-legrand) 46:549-561, 2000
62. Ronco C, Brendolan A, Cappelli G, et al: In vitro and in vivo evaluation of a new polysulfone membrane for hemodialysis. Reference methodology and clinical results. (Part. 2: in vivo study). Int J Artif Organs 22:616-624, 1999
63. Kandus A, Malovrh M, Bren AF: Influence of blood flow on adsorption of beta2-microglobulin onto AN69 dialyzer membrane. Artif Organs 21:903-906, 1997
64. Stiller S, Xu XQ, Gruner N, et al: Validation of a two-pool model for the kinetics of beta2-microglobulin. Int J Artif Organs 25:411-420, 2002
65. Clark WR, Macias WL, Molitoris BA, et al: Membrane adsorption of beta 2-microglobulin: Equilibrium and kinetic characterization. Kidney Int 46: 1140-1146, 1994
66. Leypoldt JK, Cheung AK, Deeter RB: Single compartment models for evaluating beta 2-microglobulin clearance during hemodialysis. ASAIO J 43:904-909, 1997
67. Ledebo I: Principles and practice of hemofiltration and hemodiafiltration. Artif Organs 22:20-25, 1998
68. Ledebo I: On-line hemodiafiltration: technique and therapy. Adv Renal Replace Ther 6:195-208, 1999
69. Schiffl H, Kuchle C, Held E: Beta-2-microglobulin removal by different hemodialysis membranes. Contrib Nephrol 112:156-163, 1995
70. Floege J, Granolleras C, Deschodt G, et al: High-flux synthetic versus cellulosic membranes for beta 2-microglobulin removal during hemodialysis, hemodiafiltration and hemofiltration. Nephrol Dial Transplant 4:653-657, 1989
71. Leypoldt JK, Cheung AK, Deeter RB: Rebound kinetics of beta2-microglobulin after hemodialysis. Kidney Int 56:1571-1577, 1999
72. Stetsiuk EA, Siniukhin VN, Danilkov AP, et al: [Beta 2-microglobulin kinetics during hemodialysis with different membranes]. Urol Nefrol (Mosk) 3:18-20, 1995
73. Westhuyzen J, Foreman K, Battistutta D, et al: Effect of dialyzer reprocessing with Renalin on serum beta-2-microglobulin and complement activation in hemodialysis patients. Am J Nephrol 12:29-36, 1992
74. DiRaimondo CR, Pollak VE: Beta 2-microglobulin kinetics in maintenance hemodialysis: A comparison of conventional and high-flux dialyzers and the effects of dialyzer reuse. Am J Kidney Dis 13:390-395, 1989
75. Canaud B, Nguyen QV, Bonnardet A, et al: Multiple use of the AN 69 membrane in hemodiafiltration: Preliminary clinical experience. Kidney Int Suppl 24:S135-136, 1988
76. Chanard J, Caudwell V, Valeire J, et al: Kinetics of 131I-beta2 microglobulin in hemodialysis patients: assessment using total body counting. Artif Organs 22:574-580, 1998
77. Lee CJ, Hsiong CH, Chang YL, et al: Statistical and parametric analysis of beta-2-microglobulin removal from uremic patients in high flux hemodialysis. ASAIO J 40:62-66, 1994
78. Sombolos K, Tsitamidou Z, Kyriazis G, et al: Clinical evaluation of four different high-flux hemodialyzers under conventional conditions in vivo. Am J Nephrol 17:406-412, 1997
79. Hoenich NA, Woffindin C, Brennan A, et al: A comparison of three brands of polysulfone membranes. J Am Soc Nephrol 7:871-876, 1996
80. Honig R, Marsen T, Schad S, et al: Correlation of beta-2-microglobulin concentration changes to changes of distribution volume. Int J Artif Organs 11:459-464, 1998
81. Kes P, Zubcic A, Ratkovic-Gusic I, et al: The effect of hollow-fiber dialyzer Plivadial Altra-Flux 140 on beta-2-microglobulin removal. Acta Med Croatica 51: 105-109, 1997
82. Leypoldt JK, Cheung AK, Deeter RB: Effect of hemodialyzer reuse: Dissociation between clearances of small and large solutes. Am J Kidney Dis 32:295-301, 1998
83. Kaplan AA: Dialyzer reuse: What we know and what we don't know. Semin Dial 13:271-274, 2000
84. Cheung AK, Agodoa LY, Daugirdas JT, et al: Effects of hemodialyzer reuse on clearances of urea and beta2-microglobulin. The Hemodialysis (HEMO) Study Group. J Am Soc Nephrol 10:117-127, 1999
85. Port FK, Wolfe RA, Hulbert-Shearon TE, et al: Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: Results from the USRDS dialysis morbidity and mortality study. Am J Kidney Dis 37:276-286, 2001
86. Castro R, Morgado T: Beta(2)-microglobulin clearance decreases with Renalin reuse. Nephron 90:347-348, 2002
87. Cornelius RM, McClung WG, Richardson RM, et al: Effects of heat/citric acid reprocessing on high-flux polysulfone dialyzers. ASAIO J 48:45-56, 2002
88. Koda Y, Nishi S, Miyazaki S, et al: Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 52:1096-1101, 1997
89. Locatelli F, Marcelli D, Conte F, et al: Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto. Kidney Int 55:286-293, 1999
90. Locatelli F, Mastrangelo F, Redaelli B, et al: Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 50:1293-1302, 1996
91. Aoike I, Gejyo F, Arakawa MLearning from the Japanese RegistryHow will we prevent long-term complications? Niigata Research Programme for beta 2-M Removal Membrane: Nephrol Dial Transplant 10:7-15, 1995 (suppl)
92. Shinzato T, Nakai S, Akiba T, et al: Report of the annual statistical survey of the Japanese Society for Dialysis Therapy in 1996. Kidney Int 55:700-712, 1999
93. Randoux C, Gillery P, Georges N, et al: Filtration of native and glycated beta2-microglobulin by charged and neutral dialysis membranes. Kidney Int 60:1571-1577, 2001
94. MacLeod A, Daly C, Khan I, et al: Comparison of cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease. Cochrane Database Syst Rev 3:CD003234, 2001
95. Kim ST, Yamamoto C, Taoka M, et al: Programmed filtration, a new method for removing large molecules and regulating albumin leakage during hemodiafiltration treatment. Am J Kidney Dis 38:S220-223, 2001
96. Combarnous F, Tetta C, Cellier CC, et al: Albumin loss in on-line hemodiafiltration. Int J Artif Organs 25:203-209, 2002
97. Menth M, Rockel A, Abdelhamid S, et al: Low-molecular-weight protein-permeable cuprammonium rayon haemofilter. Nephrol Dial Transplant 7:844-847, 1992
98. Shinzato T, Miwa M, Nakai S, et al: Alternate repetition of short fore- and backfiltrattons reduces convective albumin loss. Kidney Int 50:432-435, 1996
99. Kunitomo T: First International Course on Hemodialysis Technology, Vicenza, Italy, June 2002
100. Kramer B, Pickert A, Hohmann, et al: In vivo clearance and elimination of nine marker substances during hemofiltration with different membranes. Int J Artif Organs 15:408-412, 1992
101. Di Filippo S, Manzoni C, Locatelli F: Efficiency parameters and treatment adequacy of hemodialysis and hemodiafiltration using polymethylmethacrylate membranes. Contrib Nephrol 125:86-95, 1998
102. Floege J, Wilks M, Shaldon S, et al: Beta 2-microglobulin kinetics during haemofiltration. Nephrol Dial Transplant 3:784-789, 1988
103. Kerr PB, Argiles A, Flavier JL, et al: Comparison of hemodialysis and hemodiafiltration: A long-term longitudinal study. Kidney Int 41:1035-1040, 1992
104. Lin CL, Yang CW, Chiang CC, et al: Long-term on-line hemodiafiltration reduces predialysis beta-2-microglobulin levels in chronic hemodialysis patients. Blood Purif 19:301-307, 2001
105. Pedrini LA, De Cristofaro V, Pagliari B, et al: Mixed predilution and postdilution online hemodiafiltration compared with the traditional infusion modes. Kidney Int 58:2155-2165, 2000
106. Muller-Steinhardt M, Kock N, Hartel C, et al: Production of monokines in patients under polysulphone haemodiafiltration is influenced by the ultrafiltration flow rate. Nephrol Dial Transplant 16:1830-1837, 2001
107. Lornoy W, Becaus I, Billiouw JM, et al: On-line haemodiafiltration. Remarkable removal of beta2-microglobulin. Long-term clinical observations. Nephrol Dial Transplant 15:49-54, 2000
108. Wizemann V, Lotz C, Techert F, et al: On-line haemodiafiltration versus low-flux haemodialysis: A prospective randomized study. Nephrol Dial Transplant 15(suppl):43-48, 2000
109. Ward RA, Schmidt B, Hullin J, et al: A comparison of on-line hemodiafiltration and high-flux hemodialysis: A prospective clinical study. J Am Soc Nephrol 11:2344-2350, 2000
110. Lim PS, Lin HM, Yeh CH, et al: Clinical experience with on-line hemodiafiltration. Acta Nephrologica 10:127-132, 1996
111. Tang HL, Tsang WK, Fung KS, et al: On-line hemodiafiltration and high-flux hemodialysis: Comparison of efficiency and cost analysis. Hong Kong J Nephrol 3:21-26, 2001
112. Takenaka T, Itaya Y, Tsuchiya Y, et al: Fitness of biocompatible high-flux hemodiafiltration for dialysis-related amyloidosis. Blood Purif 19:10-14, 2001
113. Maduell F, del Pozo C, Garcia H, et al: Change from conventional haemodiafiltration to on-line haemodiafiltration. Nephrol Dial Transplant 141202-141207, 1999
114. Wei SS, Paganini EP, Cressman MD, et al: Use of hemodiafiltration to enhance delivered dialysis. ASAIO J 40:977-980, 1994
115. Locatelli F, Di Filippo S, Manzoni C: Removal of small and middle molecules by convective techniques. Nephrol Dial Transplant 15:37-44, 2000
116. Reynolds JT, Cantey L, Evans E, et al: A one-year prospective trial of short daily hemodialysis (SDHD): Clinical parameters. J Am Soc Nephrol 13:60A(abstr), 2002
117. Fagugli RM, De Smet R, Buoncristiani U, et al: Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis 40:339-347, 2002
118. 2-Microglobulin kinetics in nocturnal haemodialysis. Nephrol Dial Transplant 15:58-64, 2000
119. Morena M, Teehan G, Meyer K, et al: Daily hemofiltration attenuates circulating pro-inflammatory markers and cytokine responsiveness in patients with end-stage renal disease. J Am Soc Nephrol 13:411A, 2002 (abstr)
120. Kubo S, Date H: Clinical usefulness of frequent short-time hemodiafiltration: Trial for the effective removal of beta-2-microglobulin. Nephron 72:93-97, 1996
121. Nakazawa R, Azuma N, Suzuki M, et al: A new treatment for dialysis-related amyloidosis with beta 2-microglobulin adsorbent column. Int J Artif Organs 16:823-829, 1993
122. Gejyo F, Suzuki S, Arakawa M: Dialysis-related amyloidosis and clinical significance of extracorporeal removal of beta2-microglobulin. Ther Apher 1:126-128, 1997
123. Hyodo T, Tiara T, Hiyama E, et al: The clinical study on the newer type (Lixelle Type S-15) of the direct hemoperfusion B2-MG adsorption column. J Am Soc Nephrol 12:267A, 2001 (abstr)
124. Silberzweig J, Brener Z, Kuntsevich V, et al: Efficient removal of small molecular weight proteins with a broad-spectrum hemoadsorption device (BetaSorb 500) combined with high-flux dialysis in ESRD subjects. Am Soc Artif Intern Organs 49:67, 2003
125. Gejyo F, Homma N, Hasegawa S, et al: A new therapeutic approach to dialysis amyloidosis: Intensive removal of beta 2-microglobulin with adsorbent column. Artif Organs 17:240-243, 1993
126. Homma N, Gejyo F, Hasegawa S, et al: Effects of a new adsorbent column for removing beta-2-microglobulin from circulating blood of dialysis patients. Contrib Nephrol 112:164-171, 1995
127. Tsuchida K, Takemoto Y, Sugimura K, et al: Adsorption of endotoxin by beta2-microglobulin adsorbent column (Lixelle): The new approach for endotoxinemia. Ther Apher 6:116-118, 2002
128. Tsuchida K, Takemoto Y, Nakatani T, et al: Adsorption of microorganism components by lixelle beads. Artif Organs 24:577-580, 2000
129. Tsuchida K, Takemoto Y, Nakamura T, et al: Lixelle adsorbent to remove inflammatory cytokines. Artif Organs 22:1064-1067, 1998
130. Furuyoshi S, Nakatani M, Taman J, et al: New adsorption column (Lixelle) to eliminate beta2-microglobulin for direct hemoperfusion. Ther Apher 2:13-17, 1998
131. 2-microglobulin on the treatment of dialysis-related amyloidosis. Artif Organs 19:1222-1226, 1995
132. Tsuchida K, Takemoto Y, Sugimura K, et al: Direct hemoperfusion by using Lixelle column for the treatment of systemic inflammatory response syndrome. Int J Mol Med 10:485-488, 2002
133. Kaneko T, Kudo M, Okumura T, et al: Successful treatment of digoxin intoxication by haemoperfusion with specific columns for beta2-microgloblin-adsorption (Lixelle) in a maintenance haemodialysis patient. Nephrol Dial Transplant 16:195-196, 2001
134. Hiyama E, Hyodo T, Kondo M, et al: Performance of the newer type (Lixelle Type S-15) on direct hemoperfusion beta-2-microglobulin adsorption column for dialysis-related amyloidosis. Nephron 92: 501-502, 2002
135. Shiota E, Fujinaga M: Remission of a recurrent carpal tunnel syndrome by a new device of the hemodialysis method in a long-term hemodialysis patient. Clin Nephrol 53:230-234, 2000
136. Ronco C, Brendolan A, Winchester JF, et al: First clinical experience with an adjunctive hemoperfusion device designed specifically to remove beta 2-microglobulin in hemodialysis. Contrib Nephrol 133:166-173, 2001
137. Winchester FJ, Ronco C, Salsberg J, et al: Sorbent augmented dialysis systems. Contrib Nephrol 137: 170-180, 2002
138. Nakano H, Gomi H, Shibasaki T, et al: An experimental study on selective elimination of β2-microglobulin using immunoadsorption method in patients with chronic renal failure. Biomat Artif Cells Immob Biotech 19:61-69, 1991
139. Ameer GA, Grovendar EA, Ting D, et al: A novel immunoadsorption device for removing β2-microglobulin from whole blood. Kidney Int 59:1544-1550, 2000
140. Muller-Schulte D, Melzer H, Mann H: Removal of β2-microglobulin using grafted affinity adsorbents as therapeutic approach for the treatment of hemodialysis patients. J Chromatogr B Biomed Sci Appl 656:135-141, 1994
141. Jadoul M, Noel H, Malghem J, et al: Histological beta-2-microglobulin amyloidosis 10 years after a successful renal transplantation. Am J Kidney Dis 27:888-890, 1996
142. Bardin T, Lebail-Darne JL, Zingraff J, et al: Dialysis arthropathy: Outcome after renal transplantation. Am J Med 99:243-248, 1995
143. Goldsmith DJ, Covic A, Sambrook P, et al: Dialysis-related beta-2-microglobulin amyloidosis after long-term dialysis, and the effect of renal transplantation and cyclosporin therapy. Am J Med 100:587-588, 1996
144. Campistol JM: Dialysis-related amyloidosis after renal transplantation. Semin Dial 14:99-102, 2001
145. Mourad G, Argiles A: Renal transplantation relieves the symptoms but does not reverse beta 2-microglobulin amyloidosis. J Am Soc Nephrol 7:798-804, 1996
146. Schwalbe S, Holzhauer M, Schaeffer J, et al: Beta 2-microglobulin associated amyloidosis: A vanishing complication of long-term hemodialysis? Kidney Int 52:1077-1083, 1997
147. Nakai S, Iseki K, Tabei K, et al: Outcomes of hemodiafiltration based on Japanese dialysis patient registry. Am J Kidney Dis 38(suppl):S212-216, 2001, 2001
148. Leypoldt JK, Cheung AK, Carroll CE, et al: Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis 33:349-355, 1999
149. Floege J, Granolleras C, Merscher S, et al: Is the rise in plasma beta-2-microglobulin seen during hemodialysis meaningful? Nephron 51:6-12, 1989
150. Mrowka C, Schiffl H: Comparative evaluation of beta 2-microglobulin removal by different hemodialysis membranes: A six-year follow-up. Nephron 63:368-369, 1998
151. Zingraff J, Beyne P, Urena P, et al: Influence of haemodialysis membranes on beta 2-microglobulin kinetics: In vivo and in vitro studies. Nephrol Dial Transplant 3:284-290, 1988
152. Nensel U, Rockel A, Hillenbrand T, et al: Dialyzer permeability for low-molecular-weight proteins. Comparison between polysulfone, polyamide and cuprammonium-rayon dialyzers. Blood Purif 12:128-134, 1994
153. Ronco C, Heifetz A, Fox K, et al: Beta 2-microglobulin removal by synthetic dialysis membranes. Mechanisms and kinetics of the molecule. Int J Artif Organs 20:136-143, 1997
154. Timokhov VS, Kazakov IV, Toritsina LK, et al: The removal of beta 2-microglobulin during continuous and intermittent hemofiltration. Urol Nefrol (Mosk) 5:47-51, 1989
155. Zingraff J, Beyne P, Urena P, et al: Influence of haemodialysis membranes on beta 2-microglobulin kinetics: In vivo and in vitro studies. Nephrol Dial Transplant 3:284-290, 1988
156. Goldman M, Dhaene M, Vanherweghem JL: Removal of beta 2-microglobulin by adsorption on dialysis membranes. Nephrol Dial Transplant 2:576-577, 1987
157. Floge J, Granolleras C, Smeby L, et al: Hydrophilic high flux polyamide membranes for beta-2-microglobulin removal. ASAIO Trans 33:309-311, 1987
158. Di Giulio S, Splendiani G, Sturniolo A, et al: Microprotein kinetics in dialysis. Beta-2-microglobulin and heparin-free hemodialysis. Contrib Nephrol 70: 267-271, 1989
159. Chanard J, Toupance O, Lavaud S, et al: Serum beta 2 microglobulin and extracellular fluid volume during haemodialysis. Nephrol Dial Transplant 4:549-554, 1989
160. Clark WR, Leypoldt JK, Henderson LW, et al: Quantifying the effect of changes in the hemodialysis prescription on effective solute removal with a mathematical model. J Am Soc Nephrol 10:601-609, 1999
161. Gotch F, Levin N, Zasuwa G, et al: Kinetics of beta-2-microglobulin in hemodialysis. Contrib Nephrol 74:132-138, 1989
162. Karlsson FA, Groth T, Sege K, et al: Turnover in humans of beta 2-microglobulin: The constant chain of HLA-antigens. Eur J Clin Invest 10:293-300, 1980
163. Lins RL, Zachee P, Daelemans R, et al: Red blood cell function and beta 2 microglobulin kinetics during cuprophan hemodialysis: A hypothesis. Int J Artif Organs 12:638-641, 1989
164. Maeda K, Shinzato T, Ota T, et al: Beta-2-microglobulin generation rate and clearance rate in maintenance hemodialysis patients. Nephron 56:118-125, 1990
165. Risler T, Braun N, Hanel KD, et al: Do different dialysis-membranes affect beta 2-microglobulin kinetics during chronic hemodialysis? Int J Artif Organs 17:581-584, 1994
166. Woo J, Floyd M, Longley MA, et al: beta 2-Microglobulin clearance as measured by radioimmunoassay. Clin Chem 26:1193-1197, 1980
167. Xu XQ, Gruner N, Al-Bashir A, et al: Determination of extra renal clearance and generation rate of beta2-microglobulin in hemodialysis patients using a kinetic model. ASAIO J 47:623-627, 2001
168. Zaoui PM, Stone WJ, Hakim RM: Effects of dialysis membranes on beta 2-microglobulin production and cellular expression. Kidney Int 38:962-968, 1990
169. Zingraff J, Caillat-Vigneron N, Urena P, et al: Plasma kinetics of 125I-labelled amyloid P component in beta 2M amyloidosis: A possible approach to quantitate disease activity. Nephrol Dial Transplant 10: 223-229, 1995
170. Jadoul M, Garbar C, Noel H, et al: Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: A prospective post-mortem study. Kidney Int 51:1928-1932, 1997
171. Niwa T: Beta2-Microglobulin dialysis amyloid and its formation: Role of 3-deoxyglucosone and advanced glycation end products. Nephron 76:373-391, 1997
172. Davies SP, Kox WJ, Brown EA: Clearance studies in patients with acute renal failure treated by continuous arteriovenous haemodialysis. Contrib Nephrol 93:117-119, 1991
173. Kes P, Zubcic A, Ratkovic-Gusic I, et al: Beta-2-microglobulin kinetics during paired filtration dialysis. Acta Med Croatica 52:99-102, 1998